{"id":{"repo_id":"usf","oai_identifier":"oai:digitalcommons.usf.edu:etd-11689"},"canonical_url":"https://search.ndltd.org/etd/usf/oai:digitalcommons.usf.edu:etd-11689","repository":{"repo_id":"usf","name":"University of South Florida","base_url":"https://digitalcommons.usf.edu/do/oai/"},"display":{"title":"Aldosterone Treatment Protects Connexin 30 and 43 Expression for Age-Related Hearing Loss","abstract":"Age-related hearing loss (ARHL), also known as presbycusis, is the number one communication disorder affecting our aged population. Connexin proteins are essential for intercellular communication throughout the human body. Mutations in connexin genes have been linked to human syndromic and nonsyndromic deafness; thus, we hypothesize changes in connexin gene and protein expression with age may be involved in the development of ARHL. In our current study, connexin mRNA gene expression for CBA/CaJ mice at different age points were examined and correlations were analyzed between the changes in gene expression and functional hearing measures, such as ABRs and DPOAEs. Moreover, we investigated potential treatment options for ARHL. Results showed significant downregulation of Cx30 and Cx43 gene expression in the stria vascularis (SV), and meaningful correlations between the degree of hearing loss and the changes in gene expression for both genes. Moreover, dose-dependent treatments utilizing cochlear cell lines showed that H2O2 oxidative stress significantly decreased gene and protein expression for Cx30 and Cx43, while aldosterone hormone therapy significantly increased Cx expression. In vivo treatment of aging mice with aldosterone also revealed protective effects on connexin expression and ARHL. These findings support further quantitative analyses for measuring the exact effects of each treatment. Based on these functionally relevant findings, our goal is to determine more about the mechanisms related to connexin family gap junction protein expression changes during ARHL, and expand our knowledge of potential, innovative treatment options.","abstract_html":"Age-related hearing loss (ARHL), also known as presbycusis, is the number one communication disorder affecting our aged population. Connexin proteins are essential for intercellular communication throughout the human body. Mutations in connexin genes have been linked to human syndromic and nonsyndromic deafness; thus, we hypothesize changes in connexin gene and protein expression with age may be involved in the development of ARHL. In our current study, connexin mRNA gene expression for CBA/CaJ mice at different age points were examined and correlations were analyzed between the changes in gene expression and functional hearing measures, such as ABRs and DPOAEs. Moreover, we investigated potential treatment options for ARHL. Results showed significant downregulation of Cx30 and Cx43 gene expression in the stria vascularis (SV), and meaningful correlations between the degree of hearing loss and the changes in gene expression for both genes. Moreover, dose-dependent treatments utilizing cochlear cell lines showed that H2O2 oxidative stress significantly decreased gene and protein expression for Cx30 and Cx43, while aldosterone hormone therapy significantly increased Cx expression. In vivo treatment of aging mice with aldosterone also revealed protective effects on connexin expression and ARHL. These findings support further quantitative analyses for measuring the exact effects of each treatment. Based on these functionally relevant findings, our goal is to determine more about the mechanisms related to connexin family gap junction protein expression changes during ARHL, and expand our knowledge of potential, innovative treatment options.","abstract_has_math":false,"creators":["Pineros Valencia, Jennifer A."],"institution":"University of South Florida","degree_name":"Doctor of Philosophy (Ph.D.)","degree_level":"Dissertation","degree_discipline":"Biomedical Engineering","degree_department":null,"school":null,"contributors":["Robert Frisina, Ph.D.","Bo Ding, M.D.","Victoria Sanchez, Ph.D.","Mark Jaroszeski, Ph.D.","Nathan Gallant, Ph.D."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2022,"date_issued":"2022-11-21T08:00:00Z","date_published":"2022-11-21T08:00:00Z","updated_at":"2026-11-19T08:48:51Z","subjects":["Aging","Connexins","Presbycusis","Kir4.1","Drug Development","Biomedical Engineering and Bioengineering","Speech Pathology and Audiology"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.usf.edu/etd/10402","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://digitalcommons.usf.edu/etd/10402","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://digitalcommons.usf.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Adigitalcommons.usf.edu%3Aetd-11689","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Robert Frisina, Ph.D.","Bo Ding, M.D.","Victoria Sanchez, Ph.D.","Mark Jaroszeski, Ph.D.","Nathan Gallant, Ph.D."]},{"key":"dc:creator","label":"Author","values":["Pineros Valencia, Jennifer A."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2022-11-21T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Biomedical Engineering"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation","Ph.D."]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy (Ph.D.)"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of South Florida"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Aging","Connexins","Presbycusis","Kir4.1","Drug Development","Biomedical Engineering and Bioengineering","Speech Pathology and Audiology"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.usf.edu/etd/10402"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Age-related hearing loss (ARHL), also known as presbycusis, is the number one communication disorder affecting our aged population. Connexin proteins are essential for intercellular communication throughout the human body. Mutations in connexin genes have been linked to human syndromic and nonsyndromic deafness; thus, we hypothesize changes in connexin gene and protein expression with age may be involved in the development of ARHL. In our current study, connexin mRNA gene expression for CBA/CaJ mice at different age points were examined and correlations were analyzed between the changes in gene expression and functional hearing measures, such as ABRs and DPOAEs. Moreover, we investigated potential treatment options for ARHL. Results showed significant downregulation of Cx30 and Cx43 gene expression in the stria vascularis (SV), and meaningful correlations between the degree of hearing loss and the changes in gene expression for both genes. Moreover, dose-dependent treatments utilizing cochlear cell lines showed that H2O2 oxidative stress significantly decreased gene and protein expression for Cx30 and Cx43, while aldosterone hormone therapy significantly increased Cx expression. In vivo treatment of aging mice with aldosterone also revealed protective effects on connexin expression and ARHL. These findings support further quantitative analyses for measuring the exact effects of each treatment. Based on these functionally relevant findings, our goal is to determine more about the mechanisms related to connexin family gap junction protein expression changes during ARHL, and expand our knowledge of potential, innovative treatment options."]},{"key":"dc:title","label":"Title","values":["Aldosterone Treatment Protects Connexin 30 and 43 Expression for Age-Related Hearing Loss"]}]}],"canonical_facts":{"dc:contributor":["Robert Frisina, Ph.D.","Bo Ding, M.D.","Victoria Sanchez, Ph.D.","Mark Jaroszeski, Ph.D.","Nathan Gallant, Ph.D."],"dc:creator":["Pineros Valencia, Jennifer A."],"dc:date":["2022-11-21T08:00:00Z"],"dc:description":["Age-related hearing loss (ARHL), also known as presbycusis, is the number one communication disorder affecting our aged population. Connexin proteins are essential for intercellular communication throughout the human body. Mutations in connexin genes have been linked to human syndromic and nonsyndromic deafness; thus, we hypothesize changes in connexin gene and protein expression with age may be involved in the development of ARHL. In our current study, connexin mRNA gene expression for CBA/CaJ mice at different age points were examined and correlations were analyzed between the changes in gene expression and functional hearing measures, such as ABRs and DPOAEs. Moreover, we investigated potential treatment options for ARHL. Results showed significant downregulation of Cx30 and Cx43 gene expression in the stria vascularis (SV), and meaningful correlations between the degree of hearing loss and the changes in gene expression for both genes. Moreover, dose-dependent treatments utilizing cochlear cell lines showed that H2O2 oxidative stress significantly decreased gene and protein expression for Cx30 and Cx43, while aldosterone hormone therapy significantly increased Cx expression. In vivo treatment of aging mice with aldosterone also revealed protective effects on connexin expression and ARHL. These findings support further quantitative analyses for measuring the exact effects of each treatment. Based on these functionally relevant findings, our goal is to determine more about the mechanisms related to connexin family gap junction protein expression changes during ARHL, and expand our knowledge of potential, innovative treatment options."],"dc:identifier":["https://digitalcommons.usf.edu/etd/10402"],"dc:subject":["Aging","Connexins","Presbycusis","Kir4.1","Drug Development","Biomedical Engineering and Bioengineering","Speech Pathology and Audiology"],"dc:title":["Aldosterone Treatment Protects Connexin 30 and 43 Expression for Age-Related Hearing Loss"],"thesis:degree_discipline":["Biomedical Engineering"],"thesis:degree_level":["Dissertation","Ph.D."],"thesis:degree_name":["Doctor of Philosophy (Ph.D.)"],"thesis:institution_name":["University of South Florida"]},"updated_at":"2026-11-19T08:48:51Z"}